SPECTRAL MEDICAL INC EDT

EDT TSX
EDT
SPECTRAL MEDICAL INC TSX
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Health Technology
Industry: Medical Specialties
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. It operates through the following segments: Spectral Medical Inc., Dialco Medical Inc., and Corporate. The Spectral Medical Inc. segment seeks U.S. FDA approval for PMX for the treatment of patients with septic shock, it also manufactures and sells its Endotoxin Activity Assay (EAA) diagnostic and certain proprietary reagents. The Dialco Medical Inc. segment is in charge of seeking U.S. FDA clearance for DIMI in-home use and commercializing products for the RTT market. The Corporate segment represents centralized costs associated with the company's office and costs of being a public reporting entity. The company was founded on July 29, 1991 and is headquartered in Toronto, Canada.